Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 207628
Company: AUROBINDO PHARMA LTD

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
LEVALBUTEROL HYDROCHLORIDE LEVALBUTEROL HYDROCHLORIDE EQ 0.25% BASE SOLUTION;INHALATION Prescription AN No No

Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
01/31/2017 ORIG-1 Approval STANDARD

Label is not available on this site.
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
02/07/2020 SUPPL-4 Labeling-Package Insert

Label is not available on this site.

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION; EQ 0.25% BASE
TE Code = AN

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
LEVALBUTEROL HYDROCHLORIDE LEVALBUTEROL HYDROCHLORIDE EQ 0.25% BASE SOLUTION;INHALATION Prescription No AN 207628 AUROBINDO PHARMA LTD
LEVALBUTEROL HYDROCHLORIDE LEVALBUTEROL HYDROCHLORIDE EQ 0.25% BASE SOLUTION;INHALATION Prescription No AN 078309 MYLAN SPECIALITY LP
LEVALBUTEROL HYDROCHLORIDE LEVALBUTEROL HYDROCHLORIDE EQ 0.25% BASE SOLUTION;INHALATION Prescription No AN 200875 TEVA PARENTERAL
XOPENEX LEVALBUTEROL HYDROCHLORIDE EQ 0.25% BASE SOLUTION;INHALATION Prescription Yes AN 020837 AKORN

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English